California, USA-based Affymax says it has obtained a commitment from institutional investors to purchase around $42.0 million of its common stock in a private placement.
Under the terms of one of two types of purchase agreements, Affymax will sell 2,844,708 newly-issued shares at a price of $11.25 each. In the other purchase accord, the company will sell 652,262 newly-issued units at $15.33 each, with each consisting of one share of common stock and one warrant to buy 0.65 of a share of common stock. The warrants are immediately exercisable at $16.78 per share and will expire five years from the date of issuance.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze